Further studies are warranted to elucidate the long-term outcomes and optimal usage of combined metformin and PPAR agonist in the management of type 2 diabetes, with continued research exploring optimal dosing regimens, long-term effects, and personalized treatment approaches. This evidence concerns the gene PPARA and type 2 diabetes mellitus.